Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
The financial performance of AmerisourceBergen Corporation from 2017 to 2022 is characterized by a period of steady growth, a severe singular contraction in 2020, and a subsequent robust recovery. The trajectory across all earnings metrics—Net Income, EBT, EBIT, and EBITDA—shows a high degree of correlation, indicating that the primary drivers of profitability were systemic rather than related to specific financing or tax adjustments.
- EBITDA Trend Analysis
- Earnings before interest, tax, depreciation, and amortization exhibited growth in the early period, rising from US$ 1,499,260 thousand in 2017 to a peak of US$ 1,877,172 thousand in 2018. Following a slight decline in 2019 to US$ 1,660,092 thousand, a significant reversal occurred in 2020, where EBITDA fell to a deficit of US$ 4,727,296 thousand. However, a strong recovery followed, with EBITDA reaching US$ 2,919,189 thousand in 2021 and further increasing to US$ 3,124,874 thousand by 2022, marking the highest level in the analyzed six-year period.
- Operating Profitability and Margin Volatility
- Earnings before interest and tax (EBIT) mirrored the EBITDA trend, experiencing a drastic collapse in 2020 to negative US$ 5,135,309 thousand. The narrow gap between EBIT and EBITDA throughout the period suggests that depreciation and amortization expenses remained relatively stable, while the massive 2020 loss was driven by operational or non-recurring charges. By 2022, EBIT stabilized at US$ 2,415,039 thousand, indicating a return to operational efficiency that exceeded pre-2020 levels.
- Net Income and Bottom-Line Performance
- Net income demonstrated extreme volatility, fluctuating from a low of negative US$ 3,408,716 thousand in 2020 to US$ 1,698,820 thousand in 2022. The recovery from the 2020 deficit was rapid, with the corporation returning to profitability in 2021. The alignment between EBT and Net Income suggests that the 2020 impact was largely pre-tax in nature, and the subsequent recovery reflects a restoration of core earning capacity.
Overall, the data indicates that the organization successfully navigated a critical financial downturn in 2020. The growth observed in 2021 and 2022 not only erased the losses of the preceding year but established a new baseline for EBITDA and Net Income that surpasses the 2017-2019 average.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Enterprise Value to EBITDA Ratio, Current
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 41,299,807) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 3,124,874) |
| Valuation Ratio | |
| EV/EBITDA | 13.22 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| Abbott Laboratories | 15.14 |
| Elevance Health Inc. | 9.21 |
| Intuitive Surgical Inc. | 35.76 |
| Medtronic PLC | 14.26 |
| UnitedHealth Group Inc. | 17.84 |
| EV/EBITDA, Sector | |
| Health Care Equipment & Services | 14.31 |
| EV/EBITDA, Industry | |
| Health Care | 19.44 |
Based on: 10-K (reporting date: 2022-09-30).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Enterprise value (EV)1 | 36,473,156) | 30,235,610) | 20,514,111) | 18,995,014) | 20,769,340) | 18,335,740) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 3,124,874) | 2,919,189) | (4,727,296) | 1,660,092) | 1,877,172) | 1,499,260) | |
| Valuation Ratio | |||||||
| EV/EBITDA3 | 11.67 | 10.36 | — | 11.44 | 11.06 | 12.23 | |
| Benchmarks | |||||||
| EV/EBITDA, Competitors4 | |||||||
| Abbott Laboratories | 15.85 | 17.42 | — | — | — | — | |
| Elevance Health Inc. | 10.26 | 10.05 | — | — | — | — | |
| Intuitive Surgical Inc. | 40.96 | 44.10 | — | — | — | — | |
| Medtronic PLC | 14.99 | 24.41 | — | — | — | — | |
| UnitedHealth Group Inc. | 15.11 | 17.39 | — | — | — | — | |
| EV/EBITDA, Sector | |||||||
| Health Care Equipment & Services | 15.26 | 18.05 | — | — | — | — | |
| EV/EBITDA, Industry | |||||||
| Health Care | 14.00 | 14.33 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 36,473,156 ÷ 3,124,874 = 11.67
4 Click competitor name to see calculations.
The enterprise value (EV) demonstrates a significant long-term growth trajectory, increasing from 18.3 billion USD in 2017 to 36.5 billion USD by 2022. While the growth was moderate between 2017 and 2020, a sharp acceleration occurred after September 30, 2020, with the EV rising by approximately 78% over the final two years of the period.
- EBITDA Performance and Volatility
- Earnings before interest, tax, depreciation, and amortization exhibited substantial volatility. After growing to 1.88 billion USD in 2018, EBITDA plummeted to a negative 4.73 billion USD in 2020. This anomaly represents a severe disruption in operational profitability for that fiscal year. However, a robust recovery followed, with EBITDA returning to positive territory at 2.92 billion USD in 2021 and further increasing to 3.12 billion USD in 2022.
- EV/EBITDA Ratio Stability
- Despite the extreme fluctuations in underlying EBITDA and the rapid escalation of enterprise value, the EV/EBITDA ratio remained remarkably stable. Excluding the 2020 period where the ratio was not applicable due to negative earnings, the multiple fluctuated within a narrow range between 10.36 and 12.23. This suggests that the market valuation of the enterprise has largely expanded in tandem with its recovered earning capacity.
- Valuation Trends
- The ratio reached its peak in 2017 at 12.23 and hit its lowest point in 2021 at 10.36. The slight uptick to 11.67 in 2022 indicates a return toward historical valuation norms as the enterprise value continued to climb faster than the growth in EBITDA during the final year of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?